UNSPSC 51261704: Icatibant

This classification denotes an adrenergic beta-antagonist, non-steroidal anti-inflammatory agent, and antiasthmatic agent with the molecular formula C59H89N19O13S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7PG89G35Q7, chemically known as l-arginine, d-arginyl-l-arginyl-l-prolyl-trans-4-hydroxy-l-prolylglycyl-3-(2-thienyl)-l-alanyl-l-seryl-d-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-l-(2alpha,3abeta,7abeta)-octahydro-1h-indole-2-carbonyl- but generally known as icatibant, which bears US NIH Compound Identifier 71364.

UNSPSC 51261704 Icatibant is a Commodity code that captures pharmaceutical products and related health-system supplies procured by state and local health agencies, though recent activity under this code shows significant scope misalignment. Seminole County, Florida's IFB60459723LAS procurement nominally tagged to this code actually solicits naloxone and drug deactivation systems—emergency response supplies rather than the specific pharmaceutical agent (icatibant, a bradykinin B2-receptor antagonist used for hereditary angioedema). The Texas Health and Human Services Commission's RFI HHS0017013 explores direct-to-manufacturer prescription fulfillment capabilities more broadly, testing vendor capacity for negotiated net-pricing models outside traditional pharmacy benefit manager and group purchasing organization channels. These recent records suggest the code captures a wider range of pharmaceutical procurement and health-supply contracting than the icatibant name alone indicates, with state health departments and county health systems as the primary issuing bodies.

Geographic activity concentrates in Florida and Texas based on recent postings. Seminole County's naloxone and deactivation-systems procurement (IFB, response due July 26, 2023, though posted June 30, 2026) targets quarterly deliveries to its community health building in Sanford with an initial two-year contract term and one-year renewal option. Texas HHS's RFI (posted April 3, 2026, response deadline April 3, 2026) operates as an exploratory market-intelligence phase designed to inform future RFP strategy and vendor selection for direct-to-manufacturer prescription programs. Neither solicitation names specific budget ranges or set-aside designations, though the Seminole County procurement requires E-Verify compliance, drug-free workplace certification, and standard insurance coverage, with potential FEMA funding and associated federal compliance requirements including Clean Air Act and Federal Water Pollution Control Act adherence.